As on February 19, 2021, Arbutus Biopharma Corporation (NASDAQ: ABUS) got off with the flyer as it spiked 2.57% to $4.39. During the day, the stock rose to $4.65 and sunk to $4.30 before settling in for the price of $4.28 at the close. Taking a more long-term approach, ABUS posted a 52-week range of $0.88-$9.02.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -16.70%. Meanwhile, its Annual Earning per share during the time was -9.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -137.80%. This publicly-traded company’s shares outstanding now amounts to $79.49 million, simultaneously with a float of $63.55 million. The organization now has a market capitalization sitting at $363.40 million. At the time of writing, stock’s 50-day Moving Average stood at $4.06, while the 200-day Moving Average is $3.14.
While finding the extent of efficiency of the company that is accounted for 80 employees. It has generated 75,138 per worker during the last fiscal year. Meanwhile, its income per employee was -1,921,538. The stock had 3.98 Receivables turnover and 0.04 Total Asset turnover. For the Profitability, stocks operating margin was -1186.91 and Pretax Margin of -2519.66.
Arbutus Biopharma Corporation (ABUS) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Arbutus Biopharma Corporation’s current insider ownership accounts for 1.50%, in contrast to 27.90% institutional ownership. According to the most recent insider trade that took place on Feb 09, this organization’s Chief Business Officer sold 20,000 shares at the rate of 5.00, making the entire transaction reach 100,000 in total value, affecting insider ownership by 1,307,457. Preceding that transaction, on Dec 14, Company’s Chief Business Officer sold 40,000 for 5.00, making the whole transaction’s value amount to 200,032. This particular insider is now the holder of 1,327,457 in total.
Arbutus Biopharma Corporation (ABUS) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 9/29/2020, the company posted -$0.27 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.22) by -$0.05. This company achieved a net margin of -2557.36 while generating a return on equity of -112.63. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
Arbutus Biopharma Corporation’s EPS decrease for this current 12-month fiscal period is -137.80% and is forecasted to reach -0.88 in the upcoming year.
Arbutus Biopharma Corporation (NASDAQ: ABUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arbutus Biopharma Corporation (ABUS). It’s Quick Ratio in the last reported quarter now stands at 15.90. The Stock has managed to achieve an average true range (ATR) of 0.33. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 59.57.
In the same vein, ABUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.24, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -0.88 at the market close of one year from today.
Technical Analysis of Arbutus Biopharma Corporation (ABUS)
Through scrutinizing the latest numbers posted by the [Arbutus Biopharma Corporation, ABUS], it can be observed that its last 5-days Average volume of 2.07 million was lower the volume of 3.2 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 30.81% While, its Average True Range was 0.34.
Raw Stochastic average of Arbutus Biopharma Corporation (ABUS) in the period of the previous 100 days is set at 53.02%, which indicates a major rise in contrast to 42.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 81.20% that was lower than 89.53% volatility it exhibited in the past 100-days period.